CD274 and non-small cell lung carcinoma: The median rwToT of 7.4 months for all patients with ECOG PS 0–1 was consistent with the analogous endpoint in KN024 (median pembrolizumab duration, 7.9 months) and the subpopulation with stage-IV NSCLC, with PD-L1 ≥ 50%, in KN042 (median, 6.6 months), as calculated in our prior study [13,22,30].